Advances in diagnosis and treatment of intestinal Behcet's disease.
- Author:
Shengxian FAN
1
;
Yousheng LI
Author Information
1. Department of General Surgery, Jinling Hospital, Nanjing University School of Medicine, Nanjing 210002, China. liys@medmail.com.cn.
- Publication Type:Journal Article
- MeSH:
Behcet Syndrome;
Colonoscopy;
Humans;
Immunosuppressive Agents;
Intestinal Diseases;
Mesalamine
- From:
Chinese Journal of Gastrointestinal Surgery
2015;18(4):408-410
- CountryChina
- Language:Chinese
-
Abstract:
Behcet's disease (BD) affects gastrointestinal tract is defined as intestinal BD. The diagnosis and therapeutic efficacy of intestinal BD are still lack of specific diagnostic method and effective treatment. Intestinal BD is diagnosed according to established criteria based on colonoscopic features and biopsy. To date, 5-aminosalicylic acid and systemic corticosteroids are established as the first-line therapy, while immunosuppressants and infliximab are used as second-line therapy for patients with glucocorticoid resistant. In the process of therapy, we need to carefully evaluate the patient's condition and be cautious about surgical treatment. Surgical intervention should only be considered in patients with serious complications. In this review, we summarize the recent advances in diagnosis, disease activity index and treatment of intestinal BD, and provide the theoretic proofs to clinical application.
